An Overview of Phase II Trial Results: Irinotecan Plus Cisplatin in Patients with Advanced Non-Small-Cell Lung Cancer

R. DeVore, D. Johnson, J. Crawford, I. Dimery, J. Eckardt, S. G. Eckhardt

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

During the 1980s, platinum-based regimens were yielding response rates typically less than 25%, median survival durations of about 25 weeks, and 1-year survival rates less than 25% in patients with advanced non-small-cell lung cancer (NSCLC). Currently, results from single institution phase II trials of agents introduced in the 1990s show a doubling of these numbers, and results from multiinstitutional trials are demonstrating response rates ranging from 30% to 40%, median survival durations of 40 weeks, and 1 year survivals of 40%. Single agent irinotecan shows significant activity against NSCLC in preclinical and early phase I/II clinical studies, with activity similar to that for other new agents. Therapeutic synergy is observed in preclinical tumor models when irinotecan and cisplatin are combined, and phase I/II trials of this combination have demonstrated response rates ≥ 50%. Herein the author provides an overview of data from phase II trials of irinotecan and focuses on preliminary results of a large US multicenter phase II trial of weekly irinotecan plus monthly cisplatin in 52 patients with advanced NSCLC. A response rate of 28.9% (95% CI, 16.5%-41.2%) and a median survival of 9.9 months were observed in this trial. US studies to design a more optimal irinotecan/ cisplatin regimen in the same patient population are ongoing, and early results are encouraging.

Original languageEnglish (US)
Pages (from-to)79-83
Number of pages5
JournalONCOLOGY
Volume12
Issue number8 SUPPL.
StatePublished - Dec 1 1998

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

DeVore, R., Johnson, D., Crawford, J., Dimery, I., Eckardt, J., & Eckhardt, S. G. (1998). An Overview of Phase II Trial Results: Irinotecan Plus Cisplatin in Patients with Advanced Non-Small-Cell Lung Cancer. ONCOLOGY, 12(8 SUPPL.), 79-83.